hyperwave-exhausted.blogspot.com
The biopharmaceutical industry has argued that the five years of protectiom offered by Waxmanin H.R. 1427 would stifle But the in a report earlier this montb said the 12 to 14 years that the industryu has said publicly that it wantas also would hurt innovation anddelay patients’ acces s to cheaper drugs. Eshoo’s H.R. 1548 callss for a 12-year period of data basically protecting the patents covering innovativebiotech therapies.
In a letterr to Waxman, Nancy-Ann DeParle, Obama’s health-carer reform director, and budget directo r Peter Orszagsaid “the seven-yeart policy in the FY 2010 Budger is a generous compromisse between what the FTC research has concluded and what the pharmaceutica industry has advocated.” , however, said it is “extremel y concerned” that the seven-year plan is “a risk shortcut to biosimilars.
” “We believe this abbreviated perioed will undermine the incentives necessaryu for continued biotech research into breakthrough medicinee and cures for diseases such as cancer, multiplde sclerosis, Alzheimer’s and HIV/AIDS as well as unmet medicall needs,” BIO President and CEO Jim Greenwood said in a Besides patent exclusivity, the industry has argued that drugs like those developeds by South San Francisco’s and other biotech companiexs can’t be copied like pharmaceuticao drugs because they are complez to make and the finishedr products can differ.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment